Medication costs for COVID-19 patients hospitalized in the United States have dropped sharply since May, reflecting advances in treatment, shorter stays and use of cheaper generic drugs. Research by
Gilead Sciences investigational treatment for moderately to severely active rheumatoid arthritis won't be approved by the U.S. Food and Drug Administration in current form, its partner Galapagos sai
Gilead Sciences (GILD) has received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for filgotinib, an investigational treatment fo
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the New Drug Application (NDA) for filgotinib, an

Gilead announces another cancer deal

12:18pm, Tuesday, 18'th Aug 2020
Shares of Gilead Sciences Inc. gained 0.3% in premarket trading on Tuesday after the drugmaker on Monday evening announced a deal worth more than $6 billion with Tango Therapeutics. The collaboration
Gilead Sciences (GILD) and Tango Therapeutics have announced an expanded collaboration focusing on targeted immune evasion therapies for cancer patients.Under the deal, which builds on a previous 2018
Gilead Sciences, Inc. (Nasdaq: GILD) and Tango Therapeutics today announced an expanded strategic collaboration focused on the discovery, development and commercialization of innovative targeted immun
Shares of Merck (ticker: MRK), now around $83, are down 8% this year. For investors looking for a strong pharmaceutical play at a reasonable price, Merck should get attention. “Merck speaks softly
Shares of Merck (ticker: MRK), now around $83, are down 8% this year. For investors looking for a strong pharmaceutical play at a reasonable price, Merck should get attention. “Merck speaks softly

A Field Guide to Covid-19 Vaccines and Antivirals

08:55pm, Thursday, 13'th Aug 2020
Canadian small-cap biotech CytoDyn has asked the FDA to grant the company’s drug, Leronlimab, an emergency-use authorization to treat mild to moderate Covid-19 cases.
Zydus Cadila on Thursday launched the cheapest generic version of Gilead Sciences' antiviral drug remdesivir in India to treat COVID-19 following reports of shortages at hospitals in the world's third
California Public Employees Retirement System (CalPERS) disclosed Wednesday that it more than doubled its shares stakes in Gilead Sciences Inc. and Zoom Video Communications Inc. , both of which have

Is Diodes (NASDAQ:DIOD) Using Too Much Debt?

12:25pm, Wednesday, 12'th Aug 2020
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Diodes Incorporated (NASDAQ:DIOD), is not the largest company out there, but it received a lot of attention from a...
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE